Arash Pezhouman1, Sepideh Madahian1, Hayk Stepanyan1, Hayk Ghukasyan1, Zhilin Qu1, Luiz Belardinelli2, Hrayr S Karagueuzian3. 1. Translational Arrhythmia Research Section, UCLA Cardiovascular Research Laboratory, Department of Medicine Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, California. 2. Gilead Sciences Inc., Foster City, California. 3. Translational Arrhythmia Research Section, UCLA Cardiovascular Research Laboratory, Department of Medicine Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, California. Electronic address: hkaragueuzian@mednet.ucla.edu.
Abstract
BACKGROUND: Enhanced late inward Na current (INa-L) modulates action potential duration (APD) and plays a key role in the genesis of early afterdepolarizations (EADs) and delayed afterdepolarizations (DADs) and triggered activity. OBJECTIVE: The purpose of this study was to define the influence of selective block of INa-L on EAD- and DAD-mediated triggered ventricular tachycardia (VT) and ventricular fibrillation (VF) in intact hearts using (GS967), a selective and potent (IC50 = 0.13 ± 0.01 μM) blocker of INa-L. METHODS: VT/VF were induced either by local aconitine injection (50 μg) in the left ventricular muscle of adult (3-4 months) male rats (N = 21) or by arterial perfusion of 0.1 mM hydrogen peroxide (H2O2) in aged male rats (24-26 months, N = 16). The left ventricular epicardial surface of the isolated-perfused hearts was optically mapped using fluorescent voltage-sensitive dye, and microelectrode recordings of action potentials were made adjacent to the aconitine injection site. The suppressive and preventive effects of GS967 (1 μM) against EAD/DAD-mediated VT/VF were then determined. RESULTS: Aconitine induced VT in all 13 hearts studied. Activation map (N = 6) showed that the VT was initiated by a focal activity arising from the aconitine injection site (cycle length [CL] 84 ± 12) that degenerated to VF (CL 52 ± 8 ms) within a few seconds. VF was maintained by multifocal activity with occasional incomplete reentrant wavefronts. Administration of GS967 suppressed the VT/VF in 10 of 13 hearts (P < .001). Preexposure to GS967 for 15 minutes before aconitine injection prevented initiation of VT/VF in 5 of 8 additional hearts (P < .02). VF reoccurred within 10 minutes on washout of GS967. Microelectrode recordings (N = 7) showed that VT/VF was initiated by EAD- and DAD-mediated triggered activity at CL of 86 ± 14 ms (NS from VT CL) that preceded the VF. GS967 shortened APD, flattened the slope of the dynamic APD restitution curve, and reduced APD dispersion from 42 ± 12 ms to 8 ± 3 ms (P < .01). H2O2 perfusion in eight fibrotic aged hearts promoted EAD-mediated focal VT/VF, which was suppressed by GS967 in five hearts (P < .02). CONCLUSION: The selective INa-L blocker GS967 effectively suppresses and prevents aconitine and oxidative stress-induced EADs, DADs, and focal VT/VF. Suppression of EADs, DADs, and reduction of APD dispersion make GS967 a potentially useful antiarrhythmic drug in conditions of enhanced INa-L.
BACKGROUND: Enhanced late inward Na current (INa-L) modulates action potential duration (APD) and plays a key role in the genesis of early afterdepolarizations (EADs) and delayed afterdepolarizations (DADs) and triggered activity. OBJECTIVE: The purpose of this study was to define the influence of selective block of INa-L on EAD- and DAD-mediated triggered ventricular tachycardia (VT) and ventricular fibrillation (VF) in intact hearts using (GS967), a selective and potent (IC50 = 0.13 ± 0.01 μM) blocker of INa-L. METHODS:VT/VF were induced either by local aconitine injection (50 μg) in the left ventricular muscle of adult (3-4 months) male rats (N = 21) or by arterial perfusion of 0.1 mM hydrogen peroxide (H2O2) in aged male rats (24-26 months, N = 16). The left ventricular epicardial surface of the isolated-perfused hearts was optically mapped using fluorescent voltage-sensitive dye, and microelectrode recordings of action potentials were made adjacent to the aconitine injection site. The suppressive and preventive effects of GS967 (1 μM) against EAD/DAD-mediated VT/VF were then determined. RESULTS:Aconitine induced VT in all 13 hearts studied. Activation map (N = 6) showed that the VT was initiated by a focal activity arising from the aconitine injection site (cycle length [CL] 84 ± 12) that degenerated to VF (CL 52 ± 8 ms) within a few seconds. VF was maintained by multifocal activity with occasional incomplete reentrant wavefronts. Administration of GS967 suppressed the VT/VF in 10 of 13 hearts (P < .001). Preexposure to GS967 for 15 minutes before aconitine injection prevented initiation of VT/VF in 5 of 8 additional hearts (P < .02). VF reoccurred within 10 minutes on washout of GS967. Microelectrode recordings (N = 7) showed that VT/VF was initiated by EAD- and DAD-mediated triggered activity at CL of 86 ± 14 ms (NS from VT CL) that preceded the VF. GS967 shortened APD, flattened the slope of the dynamic APD restitution curve, and reduced APD dispersion from 42 ± 12 ms to 8 ± 3 ms (P < .01). H2O2 perfusion in eight fibrotic aged hearts promoted EAD-mediated focal VT/VF, which was suppressed by GS967 in five hearts (P < .02). CONCLUSION: The selective INa-L blocker GS967 effectively suppresses and prevents aconitine and oxidative stress-induced EADs, DADs, and focal VT/VF. Suppression of EADs, DADs, and reduction of APD dispersion make GS967 a potentially useful antiarrhythmic drug in conditions of enhanced INa-L.
Authors: Norishige Morita; Jong Hwan Lee; Yuanfang Xie; Ali Sovari; Zhilin Qu; James N Weiss; Hrayr S Karagueuzian Journal: J Am Coll Cardiol Date: 2011-01-18 Impact factor: 24.094
Authors: Yejia Song; John C Shryock; Stefan Wagner; Lars S Maier; Luiz Belardinelli Journal: J Pharmacol Exp Ther Date: 2006-03-24 Impact factor: 4.030
Authors: Norishige Morita; Jong-Hwan Lee; Aneesh Bapat; Michael C Fishbein; William J Mandel; Peng-Sheng Chen; James N Weiss; Hrayr S Karagueuzian Journal: Am J Physiol Heart Circ Physiol Date: 2011-04-08 Impact factor: 4.733
Authors: Arvinder K Dhalla; Wei-Qun Wang; Joan Dow; John C Shryock; Luiz Belardinelli; Anil Bhandari; Robert A Kloner Journal: Am J Physiol Heart Circ Physiol Date: 2009-09-18 Impact factor: 4.733
Authors: Erin M Baker; Christopher H Thompson; Nicole A Hawkins; Jacy L Wagnon; Eric R Wengert; Manoj K Patel; Alfred L George; Miriam H Meisler; Jennifer A Kearney Journal: Epilepsia Date: 2018-05-21 Impact factor: 5.864
Authors: Thao P Nguyen; Ali A Sovari; Arash Pezhouman; Shankar Iyer; Hong Cao; Christopher Y Ko; Aneesh Bapat; Nooshin Vahdani; Mostafa Ghanim; Michael C Fishbein; Hrayr S Karagueuzian Journal: J Physiol Date: 2016-01-18 Impact factor: 5.182
Authors: Jil C Tardiff; Lucie Carrier; Donald M Bers; Corrado Poggesi; Cecilia Ferrantini; Raffaele Coppini; Lars S Maier; Houman Ashrafian; Sabine Huke; Jolanda van der Velden Journal: Cardiovasc Res Date: 2015-01-29 Impact factor: 10.787
Authors: Tamás Hézső; Muhammad Naveed; Csaba Dienes; Dénes Kiss; János Prorok; Tamás Árpádffy-Lovas; Richárd Varga; Erika Fujii; Tanju Mercan; Leila Topal; Kornél Kistamás; Norbert Szentandrássy; János Almássy; Norbert Jost; János Magyar; Tamás Bányász; István Baczkó; András Varró; Péter P Nánási; László Virág; Balázs Horváth Journal: Sci Rep Date: 2021-05-05 Impact factor: 4.379
Authors: Arash Pezhouman; James L Engel; Ngoc B Nguyen; Rhys J P Skelton; William Blake Gilmore; Rong Qiao; Debashis Sahoo; Peng Zhao; David A Elliott; Reza Ardehali Journal: Cardiovasc Res Date: 2022-02-21 Impact factor: 13.081